Aurobindo Pharma gets USFDA’s nod for Dexamethasone Sodium Phosphate Injection

02 Dec 2015 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dexamethasone Sodium Phosphate Injection USP, 4 mg/mL (1 ml, 5 ml and 30 ml vials). This product is expected to be launched by Q4 FY2015-16. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Dexamethasone Sodium Phosphate Injection USP, 4 mg/ml, of Luitpold Pharmaceuticals Inc. 

Dexamethasone Sodium Phosphate Injection is used in the treatment of various conditions such as severe allergic reactions, arthritis, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders and skin diseases. The approved product has an estimated market size of $31 million for the twelve months ending September 2015.

Aurobindo now has 17 ANDAs (including one tentative approval) approved out of Unit IV formulation facility in Hyderabad, India for manufacturing general injectable products. The company now has a total of 220 ANDA approvals (192 Final approvals including 10 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×